Alex Trebek, host of the popular game show Jeopardy! died today, Nov. 8, 2020, according to a tweet from Jeopardy!. He was 80 years old.
Alex Trebek, host of the popular game show Jeopardy! died today, Nov. 8, 2020, according to a tweet from Jeopardy!. He was 80 years old.
“Jeopardy! is saddened to share that Alex Trebek passed away peacefully at home early this morning, surrounded by family and friends. Thank you, Alex,” the tweet read.
In March of 2019, Trebek announced that he was given a diagnosis of stage IV pancreatic cancer. Two months later, in May, he discussed his diagnosis, treatment, and resulting depression during an interview on ABC’s Good Morning America.
“I have had kidney stones, I have had ruptured disks, so I am used to dealing with pain,” he said during the interview with Robin Roberts. “But what I am not used to dealing with is these surges that come on suddenly of deep, deep sadness. And it brings tears to my eyes.”
Unsuspecting viewers of the show may not have realized that Trebek was facing such difficulties, as he continued out his hosting duties of Jeopardy!; Trebek had been the face of the show for more than 3 decades.Trebek had been the face of the show for more than 3 decades. In May, the game show host said that his cancer was, “near remission.”
However, in a July interview with “The New York times,” Trebek, a Canadian native, discussed that the disease — and its treatments – were leaving him feeling ill.
Trebek is being remembered fondly on social media, with former contestant James Holzhauer tweeting, "It was one of the great privileges of my life to spend time with this courageous man while he fought the battle of his life. You will never be replaced in our hearts, Alex."
Subscribe to our emails for the latest updates in oncology nursing.
FDA Approves T-DXd for Previously Treated HER2-Low and -Ultralow Metastatic Breast Cancer
Published: January 27th 2025 | Updated: January 28th 2025T-DXd has received FDA approval for the treatment of unresectable or metastatic HR+, HER2-low/-ultralow breast cancer in patients whose disease progressed on prior endocrine therapy in the metastatic setting.
ctDNA Status May Be Prognostic for DFS With Celecoxib for Stage III Resected Colon Cancer
January 26th 2025While ctDNA positivity was linked to worse overall disease-free survival (DFS) in stage III resected colon cancer, it was associated with significantly improved DFS with celecoxib compared to placebo.